News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Research On Corcept Therapeutics Inc. (CORT)'s Korlym® For Patients With Cushing's Syndrome To Be Presented At ICE/ENDO 2014



6/20/2014 10:55:46 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHICAGO, IL--(Marketwired - June 19, 2014) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, today announced that new clinical research on Korlym® (mifepristone) will be presented at the joint meeting of the International Society of Endocrinology and the Endocrine Society (ICE/ENDO 2014).

The research, including results of a long-term extension phase of Corcept's multicenter, open-label SEISMIC study of Korlym, will be presented at the conference, taking place at the McCormick Place West Convention Center in Chicago from June 21-24. Korlym is a once-daily oral treatment for patients with Cushing's syndrome who have glucose intolerance and have failed or cannot have surgery.

"Cushing's syndrome, which is caused by excessive cortisol activity, is a serious condition that has a debilitating impact on all aspects of patients' lives. The disease often significantly affects patients' metabolism, leading to extreme weight gain with abnormal fat deposits, impaired glycemic control including type 2 diabetes, muscle weakness and, commonly, psychiatric symptoms," said Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer. "Because Cushing's syndrome may be a chronic disease, it is important to monitor patients taking Korlym over time. The long-term extension study of SEISMIC includes data from patients who had been receiving treatment for as long as 3.5 years."

Cushing's syndrome is the result of excessive cortisol activity throughout the body. Cortisol is a hormone made in the adrenal glands that performs vital tasks such as regulating the metabolism of proteins, carbohydrates and fats. Cushing's syndrome afflicts 20,000 people in the United States, with approximately 3,000 to 4,000 new cases each year. Approximately half of these patients are cured by surgery.

The following abstracts highlight new research on mifepristone:

---------------------------------------------------------------------------- Date Session Poster Title Authors Time Number ---------------------------------------------------------------------------- Saturday, 11:30am- OR02-2 Late-Night Salivary Cortisol Ty Brian June 21, 1:00pm for the Diagnosis of Recurrent Carroll, MD; 2014 Cushing's Disease: Evidence of Bradley R Clinical Benefit from Early Javorsky, MD; Detection James W Findling, MD ------------------------------------------------------------------ 1:00- SAT-0671 Clinical Management in a Female Elizabeth E 3:00pm with Persistent Cushing's King, MD; Disease Treated with Simone M Mifepristone for Four Years Howell, RN, CCRA ---------------------------------------------------------------------------- Sunday, 1:00- SUN-0750 Effect of Mifepristone on Vijay Babu June 22, 3:00pm Cushing's syndrome Secondary to Balakrishnan; 2014 Bilateral Adrenal Adenomas: A Pankaj Sharda, Case Presentation MBBS, MD; Elias Said Siraj, MD ---------------------------------------------------------------------------- Monday, 1:00- MON-0439 Improved Activities of Daily Daphne T June 23, 3:00pm Living, Normal Mood and Quality Adelman, BSN, 2014 of Life: 4 Years of Treatment MBA; Simone M Data in a Premenopausal Woman Howell, RN, with Cushing's Disease CCRA -------------------------------------------------------- MON-0592 A Case Report of a 37 y/o Woman Howard A Diagnosed with Cushing's Brand, MD; Disease Presenting As Pituitary Kimberly Apoplexy after Multiple Calcagno, MA; Treatment Failures Effectively Michele Responds to Mifepristone Lamerson, RN, MS, CPNP -------------------------------------------------------- MON-0595 Discontinuation of Insulin, Kevin C.J. Oral Antidiabetic and Yuen, MD, FRCP Antihypertensive Medications in (UK); Harold I a Patient with Cushing's Magazine, PhD Disease Following Mifepristone (MIFE) Therapy -------------------------------------------------------- MON-0598 Mifepristone for Refractory Audrey Cushing's Syndrome in a Patient Elisabeth with CKD Hyperkalemia Arzamendi, MD; Undergoing Surgical Exodontia Alison Marie and Weight Loss: Semrad, DO Recommendations for Clinical/Biochemical Monitoring and Perioperative Dosing -------------------------------------------------------- MON-0663 Persistent Weight Loss in Henry G. Fein, Patients Treated with MD; T. Brooks Mifepristone (MIFE) for Vaughan III, Cushing's Syndrome: Results MD; Coleman from the Seismic & Long Term Gross; Dat Extension Studies Nguyen ----------------------------------------------------------------------------

About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that regulate the effects of the stress hormone cortisol on the body. The FDA has approved the company's first drug, Korlym® (mifepristone) 300 mg Tablets, a glucocorticoid receptor antagonist, as a once-daily oral treatment for hyperglycemia secondary to endogenous Cushing's syndrome in adult patients with glucose intolerance or diabetes mellitus type 2 who have failed surgery or are not candidates for surgery. Corcept is exploring mifepristone (the active ingredient in Korlym) as a treatment for triple-negative breast cancer with a multi-center, Phase I clinical study currently underway in patients with metastatic or locally advanced unresectable breast cancer. It is also supporting investigator-led clinical studies of mifepristone in the treatment of ovarian cancer and castration-resistant prostate cancer. The company has a portfolio of selective glucocorticoid-receptor (GR) antagonists that block the effects of cortisol but not progesterone. It owns or has licensed extensive intellectual property covering the use of GR antagonists, including mifepristone, in the treatment of a wide variety of metabolic and psychiatric disorders and triple-negative breast cancer. It also holds composition of matter patents for its selective GR antagonists.


Investor Contact
Charles Robb
Corcept Therapeutics Incorporated
Chief Financial Officer
Email Contact
650-688-8783

Media Contact
Brian Baxter for Corcept
Lazar Partners Ltd.
Email Contact
646-871-8491



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES